PCP
JAZZ icon

Perimeter Capital Partners’s Jazz Pharmaceuticals JAZZ Stock Holding History

Perimeter Capital Partners’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-5,419
Closed -$797K – 125
2014
Q2 		$797K Buy
5,419
+1,114
+26% +$154K 0.41% 118
2014
Q1 		$597K Sell
4,305
-1,391
-24% -$209K 0.3% 132
2013
Q4 		$721K Sell
5,696
-29,240
-84% -$3.03M 0.36% 119
2013
Q3 		$3.21M Sell
34,936
-23,794
-41% -$1.92M 0.6% 69
2013
Q2 		$4.04M Buy
+58,730
New +$3.59M 0.78% 27

Other funds holding JAZZ

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return
LPC
Lone Pine Capital Greenwich, Connecticut $16.4B AUM 99.7% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
WBC
Westpac Banking Corp Sydney, Australia $1.62B AUM 39.13% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Perimeter Capital Partners's JAZZ Position: Q3 2014 in Review

Perimeter Capital Partners sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2014, closing a stake of 5,419 shares — an estimated $797K sold.

Perimeter Capital Partners first reported a position in JAZZ in Q2 2013 and held it in 5 quarters. The position peaked at $4.04M in Q2 2013. 326 funds tracked by Wall St. Rank hold JAZZ as of Q3 2014.

  • Perimeter Capital Partners reported no remaining Jazz Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Perimeter Capital Partners sold 5,419 Jazz Pharmaceuticals shares in Q3 2014, an estimated $797K.
  • Perimeter Capital Partners first reported a position in Jazz Pharmaceuticals in Q2 2013 and held it in 5 quarters.
  • Perimeter Capital Partners's Jazz Pharmaceuticals position peaked at $4.04M in Q2 2013.
  • 326 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2014.

Based on Perimeter Capital Partners's 13F filing for Q3 2014, filed 10 Nov 2014.